Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Cimetidine: Distinct H2 Receptor Antagonist for Cancer an...

    2026-03-03

    Cimetidine: Distinct H2 Receptor Antagonist for Cancer and BBB Research

    Executive Summary: Cimetidine is a histamine-2 receptor (H2R) antagonist with partial agonist properties distinct from ranitidine and famotidine, enabling nuanced modulation of gastric acid secretion and H2R signaling (APExBIO). It demonstrates reproducible antitumor activity in gastrointestinal cancer models, attributed to its distinct interaction with H2R and downstream pathways (Hu et al., 2025). Cimetidine is highly soluble in DMSO (≥12.62 mg/mL), ethanol (≥9.37 mg/mL), and water under specific conditions (≥2.54 mg/mL with warming/ultrasonication), supporting diverse assay workflows (APExBIO). Its purity is verified at ~98% by HPLC and NMR. The compound is not indicated for diagnostic or clinical use; it is optimized for research applications requiring rigorous reproducibility and validated pharmacological benchmarks.

    Biological Rationale

    Cimetidine (SKU B1557) is a synthetic inhibitor of the histamine-2 receptor (H2R) found predominantly in gastric parietal cells. H2R antagonists modulate gastric acid secretion, a process central to gastrointestinal physiology and pathology. Cimetidine's partial agonist activity allows for graded inhibition of H2R signaling, offering mechanistic flexibility for research on gastric acid-related conditions and cancer biology (see mechanistic deep dive; this article extends the discussion with new evidence from high-throughput BBB models). Recent studies highlight the relevance of H2R modulation in tumor microenvironments, especially in gastrointestinal cancers where histaminergic signaling intersects with proliferation and immune evasion. Cimetidine's ability to influence these processes makes it an attractive tool for research beyond classical acid suppression (see comparative analysis; this dossier updates solubility and workflow data).

    Mechanism of Action of Cimetidine

    Cimetidine competitively inhibits the binding of histamine to the H2 receptor. Unlike ranitidine and famotidine, it functions as a partial agonist, meaning it can both block and modestly activate the receptor under specific cellular conditions (mechanistic insight). This activity leads to a decrease in cyclic AMP (cAMP) production and subsequent inhibition of gastric acid secretion. The partial agonism also modifies H2R-mediated signaling cascades, influencing cell proliferation and immune regulation—key factors in cancer research. In blood-brain barrier (BBB) studies, cimetidine's transport and permeability characteristics are further modulated by its interaction with efflux transporters such as P-glycoprotein (P-gp), a feature confirmed in recent high-throughput in vitro models (Hu et al., 2025).

    Evidence & Benchmarks

    • Cimetidine exhibits partial agonist activity at the H2 receptor, distinct from full antagonists, enabling dual modulation of H2R signaling (read more).
    • In preclinical gastrointestinal cancer models, cimetidine demonstrates measurable antitumor effects, including inhibition of cell proliferation and immunomodulatory actions (internal summary).
    • High-throughput BBB permeability assays (LLC-PK1-MDR1 model) show cimetidine is subject to P-gp-mediated efflux and displays moderate passive diffusion across the barrier (Hu et al., 2025, DOI).
    • Cimetidine achieves solubility of ≥12.62 mg/mL in DMSO, ≥9.37 mg/mL in ethanol, and ≥2.54 mg/mL in water with gentle warming and ultrasonication (APExBIO).
    • Purity is consistently ~98%, validated by HPLC and NMR, ensuring reproducibility in research settings (APExBIO).
    • In LLC-PK1-MDR1 cell-based models, cimetidine's permeability parameters correlate with in vivo brain distribution, supporting its use in CNS drug screening workflows (Hu et al., 2025, DOI).

    Common Pitfalls or Misconceptions

    • Not a clinical therapeutic: Cimetidine from APExBIO is intended strictly for research use and is not approved for diagnostic or medical applications.
    • Partial agonist, not a pure antagonist: Misclassification as a strict antagonist can lead to misinterpretation of signaling data; its partial agonist activity affects downstream pathways differently.
    • Solubility dependent on protocol: Maximum solubility in water requires gentle warming and ultrasonication; failure to do so may result in incomplete dissolution.
    • Short-term solution stability: Prepared solutions are for short-term use only; long-term storage can compromise integrity, even at -20°C.
    • Efflux and transporter effects: Overlooking P-gp mediated efflux may misrepresent BBB permeability results in CNS research contexts.

    Applications, Limits & Misconceptions

    Cimetidine is widely utilized in studies of gastric acid secretion inhibition, H2 receptor signaling, and antitumor mechanisms in gastrointestinal cancers. Its partial agonist profile supports nuanced interrogation of H2R pathways in cell proliferation, immune modulation, and cancer microenvironments. In CNS drug research, cimetidine serves as a model substrate for evaluating blood-brain barrier permeability and efflux transporter activity (Hu et al., 2025).

    However, it is not a substitute for clinical-grade pharmaceuticals and should not be used in diagnostic or therapeutic protocols. Researchers must account for its partial agonist action and solubility requirements. Interpretation of BBB permeability data must incorporate possible transporter-mediated efflux, as cimetidine is a known P-gp substrate. For further protocol guidance and troubleshooting, see this workflow guide (this article updates best practices for high-throughput BBB models).

    Workflow Integration & Parameters

    Cimetidine (SKU B1557) from APExBIO is supplied as a solid, high-purity compound. It is recommended to dissolve at concentrations of:

    • DMSO: ≥12.62 mg/mL
    • Ethanol: ≥9.37 mg/mL
    • Water: ≥2.54 mg/mL, with gentle warming and ultrasonication

    Solutions should be prepared fresh or stored at -20°C for short-term use. Purity is verified by HPLC and NMR (≈98%). The compound integrates seamlessly with cell viability, proliferation, and permeability assays, especially in high-throughput formats using surrogate BBB models (e.g., LLC-PK1-MDR1) (see protocol-driven guidance; this article provides updated solubility and transporter data). The product page (Cimetidine B1557 kit) contains full technical details and recommended handling protocols.

    Conclusion & Outlook

    Cimetidine is a validated, research-grade H2 receptor modulator with unique partial agonist properties. Its solubility, purity, and mechanistic profile support advanced studies in cancer biology and blood-brain barrier research. Incorporating high-throughput model systems, such as LLC-PK1-MDR1 cells, strengthens its utility for CNS-focused screening and mechanistic interrogation (Hu et al., 2025). As research workflows evolve, cimetidine (SKU B1557, APExBIO) remains a preferred reagent for reproducible and mechanistically robust experimental outcomes.